Replimune Group, Inc. (REPL)

20.02 -0.40 (-1.96%) At close: 04:00PM EDT

Replimune Group, Inc.

500 Unicorn Park Drive
3rd Floor
Woburn, MA 01801
United States
781 222 9600
https://www.replimune.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 206

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Philip Astley-Sparke FSA	CEO & Director	880.5k	N/A	1971
Dr. Robert Coffin Ph.D.	Founder, Pres, Chief R&D Officer and Director	785.89k	N/A	1965
Ms. Tanya N. Lewis M.S.	Chief Devel. Operations Officer	4.7k	N/A	1971
Mr. Sushil Patel Ph.D.	Chief Commercial Officer	594.58k	N/A	1971
Ms. Jean M. Franchi	Principal Accounting Officer, CFO, Treasurer, Sec. & Compliance Officer	N/A	N/A	1966
Dr. Colin A. Love Ph.D.	Chief Operating Officer	N/A	N/A	1958
Dr. Pamela Esposito Ph.D.	Chief Bus. Officer	N/A	N/A	1975

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

Corporate Governance

Replimune Group, Inc.’s ISS Governance QualityScore as of July 31, 2022 is 8. The pillar scores are Audit: 9; Board: 8; Shareholder Rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.